PT-141 is the research name for bremelanotide — an FDA-approved melanocortin agonist that works on the brain, not blood flow.

The short version

Here's PT-141 in plain English. PT-141 is the lab name for bremelanotide — a small ring-shaped peptide (a short chain of amino acids joined in a loop) that flips switches in the brain rather than in your blood vessels. Those switches are melanocortin MC3R/MC4R receptors (brain controls that influence sexual desire, appetite, and skin pigment). The FDA approved it in 2019 for one thing only: persistent low sexual desire that causes real distress, in premenopausal women. It nudged desire up in trials — a genuine effect, but a small one — and the most common trade-off was nausea. Everything below is sourced. Anecdotes from forums live in a clearly-marked box, never mixed in with the studies.

PT-141 peptide: a melanocortin (MC3R/MC4R) agonist

The PT-141 peptide is a synthetic cyclic heptapeptide — seven amino acids tied into a ring (sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH), molecular weight 1025.2 Da, CAS 189691-06-3 ^[6]. It's a man-made analogue of alpha-MSH (a natural brain signaling peptide your body makes from a precursor called POMC). The ring matters: a cyclic peptide is sturdier than a straight-chain one, which is part of why this molecule survived into a finished drug.

What does it actually do? It's a melanocortin receptor agonist — meaning it switches on melanocortin receptors. There are five of them (MC1R through MC5R); PT-141 mainly hits MC4R and MC3R, the two that sit in the brain ^[1]. Activate MC4R in the hypothalamus and you tap into circuits that govern sexual motivation. That central wiring is the whole story here, and it's what separates PT-141 from the more familiar erectile-blood-flow drugs.

What is a melanocortin receptor agonist?

A melanocortin receptor agonist is any molecule that binds and activates one of the melanocortin receptors, the way a key turns a lock. PT-141 is one. Because MC4R lives in brain regions tied to desire and appetite — and MC1R lives in skin — a melanocortin agonist can influence sexual motivation centrally and, with repeated dosing, skin and gum pigment peripherally ^[4][6].

What PT-141 actually is — and what it isn't

PT-141 and bremelanotide are the same molecule. "Bremelanotide" is the official international nonproprietary name (INN); "PT-141" is the original development code. So when you read about one, you're reading about the other.

This is a real, FDA-approved prescription drug — not an untested research compound. It cleared the FDA on June 21, 2019 (NDA 210557) as bremelanotide injection ^[6]. But the approval is narrow: it covers acquired, generalized HSDD (hypoactive sexual desire disorder — persistent low sexual desire that causes real personal distress) in premenopausal women, and nothing else. Use in men, for erectile dysfunction, in postmenopausal women, or to "enhance performance" is off-label — outside what the approval supports, and backed only by early-phase research. We say so on every page.

A second thing worth nailing down: material sold online as "PT-141 research chemical" is laboratory-only material, not the approved finished drug. Nobody is checking its identity, purity, or strength. The approved product is a specific subcutaneous (injected just under the skin) drug; the powder on a research-chemical site is not that. This site is a digest of the published record — see the full reference list — not a vendor and not a clinic.

What the studies measured (and where to read more)

Across two large Phase 3 trials in premenopausal women with HSDD (the RECONNECT program, 1,267 participants), bremelanotide 1.75 mg injected as-needed beat placebo on both of its main goals over 24 weeks: sexual desire rose (FSFI desire score +0.35) and the distress about low desire fell (FSDS-DAO item 13, −0.33), each statistically significant ^[3]. Those questionnaires — FSFI and FSDS — are the standard tools trials use to score sexual desire and the distress that low desire causes.

Honest framing: those effects are real, but they're modest, and the program had setbacks along the way ^[12]. We don't oversell it. The mechanism is the genuinely interesting part — a brain-imaging study showed altered processing of erotic cues, pinning the action centrally ^[5].

From here, pick a thread: how PT-141 works and the mechanism in depth; PT-141 side effects and the foregrounded tolerability picture, including what researchers commonly report in the clearly-labeled field reports; PT-141 dosage in the research reported as trial and label findings only; and PT-141 half life, onset, and how long it lasts.

Quick answers

What is PT-141? PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that switches on central melanocortin MC3R/MC4R receptors involved in sexual desire ^[1]. It's the molecule behind the FDA-approved HSDD drug.

What is PT-141 peptide? A 7-amino-acid cyclic lactam peptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) that acts on melanocortin receptors in the brain rather than on blood vessels ^[6]. The ring shape gives it extra stability over straight-chain peptides.

What does the PT-141 peptide do? By activating MC4R (and MC3R) in hypothalamic and limbic circuits, it's thought to engage dopamine pathways that drive sexual desire and arousal ^[1][5]. It's the basis of the approved HSDD drug bremelanotide.

What is PT-141 used for? Its single FDA-approved use is acquired, generalized HSDD in premenopausal women ^[6]. Use in men, for erectile dysfunction, in postmenopausal women, or for sexual "performance" is off-label and not supported by the approval.

Is PT-141 the same as bremelanotide? Yes. "Bremelanotide" is the international nonproprietary name (INN) for the compound; "PT-141" is the original research/development code for the same molecule.

What is bremelanotide? Bremelanotide is the FDA-approved (NDA 210557, June 2019) melanocortin receptor agonist for HSDD in premenopausal women, given as a 1.75 mg subcutaneous injection as needed ^[6].